RT Journal Article
SR Electronic
T1 Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.23.20041467
DO 10.1101/2020.03.23.20041467
A1 Matthew C Sims
A1 Louisa Mayer
A1 Janine H Collins
A1 Tadbir K Bariana
A1 Karyn Megy
A1 Cecile Lavenu-Bombled
A1 Denis Seyres
A1 Laxmikanth Kollipara
A1 Frances S Burden
A1 Daniel Greene
A1 Dave Lee
A1 Antonio Rodriguez-Romera
A1 Marie-Christine Alessi
A1 William J Astle
A1 Wadie F Bahou
A1 Loredana Bury
A1 Elizabeth Chalmers
A1 Rachael Da Silva
A1 Erica De Candia
A1 Sri V V Deevi
A1 Samantha Farrow
A1 Keith Gomez
A1 Luigi Grassi
A1 Andreas Greinacher
A1 Paolo Gresele
A1 Dan Hart
A1 Marie-Françoise Hurtaud
A1 Anne M Kelly
A1 Ron Kerr
A1 Sandra Le Quellec
A1 Thierry Leblanc
A1 Eva B Leinøe
A1 Rutendo Mapeta
A1 Harriet McKin-ney
A1 Alan D Michelson
A1 Sara Morais
A1 Diane Nugent
A1 Sofia Papadia
A1 Soo J Park
A1 John Pasi
A1 Gian Marco Podda
A1 Man-Chiu Poon
A1 Rachel Reed
A1 Mallika Sekhar
A1 Hanna Shalev
A1 Suthesh Sivapalaratnam
A1 Orna Steinberg-Shemer
A1 Jonathan C Stephens
A1 Robert C Tait
A1 Ernest Turro
A1 John K M Wu
A1 Barbara Zieger
A1 NIHR BioResource
A1 Taco W Kuijpers
A1 Anthony D Whetton
A1 Albert Sickmann
A1 Kathleen Freson
A1 Kate Downes
A1 Wendy N Erber
A1 Mattia Frontini
A1 Paquita Nurden
A1 Willem H Ouwehand
A1 Remi Favier
A1 Jose A Guerrero
YR 2020
UL http://medrxiv.org/content/early/2020/03/27/2020.03.23.20041467.abstract
AB Gray platelet syndrome (GPS) is a rare recessive disorder caused by variants in NBEAL2 and characterized by bleeding symptoms, the absence of platelet ɑ-granules, splenomegaly and bone marrow (BM) fibrosis. Due to its rarity, it has been difficult to fully understand the pathogenic processes that lead to these clinical sequelae. To discern the spectrum of pathological features, we performed a detailed clinical genotypic and phenotypic study of 47 GPS patients. We identified 33 new causal variants in NBEAL2. Our GPS patient cohort exhibited known phenotypes, including macro-thrombocytopenia, BM fibrosis, megakaryocyte emperipolesis of neutrophils, splenomegaly, and elevated serum vitamin B12 levels. We also observed novel clinical phenotypes; these include reduced leukocyte counts and increased presence of autoimmune disease and positive autoantibodies. There were widespread differences in the transcriptome and proteome of GPS platelets, neutrophils, monocytes, and CD4-lymphocytes. Proteins less abundant in these cells were enriched for constituents of granules, supporting a role for Nbeal2 in the function of these organelles across a wide range of blood cells. Proteomic analysis of GPS plasma showed increased levels of proteins associated with inflammation and immune response. One quarter of plasma proteins increased in GPS are known to be synthesized outside of hematopoietic cells, predominantly in the liver. In summary, our data demonstrate that, in addition to the well-described platelet defects in GPS, there are also immune defects. The abnormal immune cells may be the drivers of systemic abnormalities, such as autoimmune disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.C.S and J.H.C. are supported by MRC Clinical Research Training Fellowships (MR/R002363/1 and MR/P02002X/1). L.M. is supported by a PhD Studentship grant from the Rosetrees Trust. T.K.B was supported by NHS Blood and Transplant and the British Society for Haematology. D.S. was in part funded by an Isaac Newton Trust/Wellcome Trust Institutional Strategic Support Fund fellowship to M.F., L.K., and A.S. acknowledge support by the Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, the Regierende Bürgermeister von Berlin - inkl. Wissenschaft und Forschung, and the Bundesministerium für Bildung und Forschung. L.B. was supported by a fellowship from Fondazione Umberto Veronesi. P.G. was supported by a Telethon Foundation Grant (GGP15063). K.F. is supported by the Research Council of the KULeuven (C14/19/096) and by unrestricted grants of Swedish Orphan Biovitrum AB, Bayer and CSL Behring. M.F. is supported by the British Heart Foundation (FS/18/53/33863). This work was performed using resources provided by the Cambridge Service for Data Driven Discovery (CSD3) operated by the University of Cambridge Research Computing Service, provided by Dell EMC and Intel using Tier-2 funding from the Engineering and Physical Sciences Research Council (EP/P020259/1), and DiRAC funding from the Science and Technology Facilities Council.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRNA-seq data has been deposited in the European Genome-phenome Archive under study accession number ID EGAD00001005950. All newly identified NBEAL2 variants have been deposited in ClinVar. Cell-type specific and plasma proteomics results have been deposited to the ProteomeXchange Consortium via the PRIDE repository at EMBL-EBI with the dataset identifiers PXD016366 and PXD017227, respectively. https://www.ebi.ac.uk/ega/datasets/EGAD00000000021 https://www.ebi.ac.uk/pride/